Medical-technology company Enovis (NYSE: ENOV) has entered a binding offer to acquire Grenoble-based eCential Robotics for an upfront enterprise value of €155 million, plus up to €35 million in milestone-based contingent payments, the two companies announced on September 1, 2026. Cash consideration of roughly €176 million will be paid to eCential shareholders at closing.
ASTRA Ecosystem Gains A Robotic Arm
The deal folds eCential's modular robotic platform into Enovis' ASTRA enabling-technology stack, which already spans surgical planning, navigation and the ARVIS augmented-reality system. CEO Damien McDonald called the transaction "more than just a robot," positioning it as the foundation for a connected orthopedic platform that runs from planning to robotic execution across hospitals, outpatient clinics and ambulatory surgery centers.
Founded on more than 15 years of computer-assisted surgery research, eCential brings 50-plus engineers with three robotic platforms behind them in orthopedics and spine. Group President of Reconstructive Louie Vogt said the French unit assembles an estimated 75 to 100 robots per year today, giving Enovis a working manufacturing base rather than a science project.
Total Knee Robot Targeted For 2028
Enovis plans to bring a next-generation robotic platform to market inside two years, starting with total knee procedures and using CT-based planning software to drive the robotic arm. A shoulder application will follow, leveraging the seven-degrees-of-freedom mechanics Enovis believes can differentiate it in a total shoulder arthroplasty market where robotic penetration is still low. The company will lean on eCential's control layer while unifying tracking, workflow and UI across ASTRA, ARVIS and the new robot.
Grenoble Becomes A Robotics Center Of Excellence
The Grenoble site will be positioned as Enovis' robotics center of excellence, feeding into a hybrid commercial model that blends distributors with enterprise-solutions personnel and clinical success managers already being stood up around ARVIS. Enovis said it will honor eCential's existing spine agreements — including its role developing Johnson & Johnson's Velys spine robot — while keeping its own R&D focused on knee and shoulder.
Deal Math And Timing
Enovis will fund the transaction from cash on hand plus revolver capacity, adding about half a turn of leverage. CFO Ben Berry sees roughly 100 basis points of adjusted EBITDA margin headwind in 2027 (150 bps of dilution offset by 50 bps of underlying gains), returning to expansion in 2028 and roughly 100 bps of improvement in 2029 as the robot ramps. Free-cash-flow conversion is still guided to about 50% next year, or at least 00 million absolute. The deal is expected to close by year-end 2026, subject to French works-council consultation and regulatory approvals; Latham & Watkins is advising Enovis.
Enovis' move lands as robotic-assisted spine and orthopedic platforms keep multiplying — Spineart's PERLA TL just won FDA clearance for robotic-assisted spine surgery, and cross-border M&A in the sector remains hot after IBM closed its HRL Laboratories deal last week.
Reporting based on coverage from GlobeNewswire, Yahoo Finance / MarketBeat and Surgical Robotics Technology.